Skip to Content

Medifocus Inc MDFZF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Medifocus Inc develops and sells minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostate Hyperplasia (BHP). It owns two focused heat technology platforms, The Endo-thermotherapy Platform-from which Prolieve was developed, can be used to treat cancers in prostate, rectal, cervical and esophageal, and The Adaptive Phased Array Microwave Focusing Platform which directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The company through its operations generates revenue from the United States.

Contact
10240 Old Columbia Road, Suite G
Columbia, MD, 21046, Canada
T +1 410 290-5734
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2019
Fiscal Year End Mar 31, 2021
Stock Type
Employees 9